PROCEPT BioRobotics Co. (NASDAQ:PRCT) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. lowered its position in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 20.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 153,006 shares of the company's stock after selling 40,179 shares during the period. Victory Capital Management Inc. owned about 0.29% of PROCEPT BioRobotics worth $12,320,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Raleigh Capital Management Inc. bought a new stake in shares of PROCEPT BioRobotics in the 4th quarter valued at about $32,000. IFP Advisors Inc purchased a new position in PROCEPT BioRobotics in the fourth quarter worth $58,000. Arcadia Investment Management Corp MI acquired a new position in shares of PROCEPT BioRobotics during the fourth quarter worth $64,000. Wilmington Savings Fund Society FSB purchased a new stake in shares of PROCEPT BioRobotics during the 3rd quarter valued at $64,000. Finally, Canton Hathaway LLC acquired a new stake in shares of PROCEPT BioRobotics in the 3rd quarter worth $66,000. 89.46% of the stock is currently owned by institutional investors.

PROCEPT BioRobotics Trading Down 2.7 %

NASDAQ:PRCT traded down $1.56 during trading hours on Thursday, hitting $56.03. The company had a trading volume of 996,207 shares, compared to its average volume of 721,940. PROCEPT BioRobotics Co. has a 1 year low of $45.56 and a 1 year high of $103.81. The company has a current ratio of 6.02, a quick ratio of 5.07 and a debt-to-equity ratio of 0.21. The company has a 50-day moving average of $71.15 and a 200 day moving average of $79.37. The company has a market cap of $3.07 billion, a P/E ratio of -28.73 and a beta of 1.06.

Remove Ads

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The firm had revenue of $68.24 million for the quarter, compared to analysts' expectations of $66.79 million. Sell-side analysts expect that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on PRCT shares. Truist Financial reissued a "buy" rating and issued a $90.00 price target (down previously from $105.00) on shares of PROCEPT BioRobotics in a report on Wednesday, February 26th. Jefferies Financial Group assumed coverage on shares of PROCEPT BioRobotics in a research report on Thursday, November 14th. They set a "hold" rating and a $95.00 target price on the stock. Wells Fargo & Company restated an "overweight" rating and issued a $112.00 price objective on shares of PROCEPT BioRobotics in a research note on Tuesday, December 3rd. Finally, Morgan Stanley cut their price target on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $94.29.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).